Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;92(7):819-823.
doi: 10.1002/jmv.25809. Epub 2020 Apr 15.

Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China

Huan Han  1 , Linlin Xie  2 , Rui Liu  1 , Jie Yang  1 , Fang Liu  3   4 , Kailang Wu  3 , Lang Chen  2 , Wei Hou  2 , Yong Feng  2 , Chengliang Zhu  1
Affiliations

Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China

Huan Han et al. J Med Virol. 2020 Jul.

Abstract

An outbreak of severe acute respiratory syndrome novel coronavirus (SARS-CoV-2) epidemic spreads rapidly worldwide. SARS-CoV-2 infection caused mildly to seriously and fatally respiratory, enteric, cardiovascular, and neurological diseases. In this study, we detected and analyzed the main laboratory indicators related to heart injury, creatine kinase isoenzyme-MB (CK-MB), myohemoglobin (MYO), cardiac troponin I (ultra-TnI), and N-terminal pro-brain natriuretic peptide (NT-proBNP), in 273 patients with COVID-19 and investigated the correlation between heart injury and severity of the disease. It was found that higher concentration in venous blood of CK-MB, MYO, ultra-TnI, and NT-proBNP were associated with the severity and case fatality rate of COVID-19. Careful monitoring of the myocardiac enzyme profiles is of great importance in reducing the complications and mortality in patients with COVID-19.

Keywords: COVID-19; disease severity; heart injury; laboratory indicators.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Figures

Figure 1
Figure 1
Levels of CK‐MB, MYO, ultra‐TnI, and NT‐proBNP of the three patients with COVID‐19 groups were compared and analyzed. According to the relevant diagnostic criteria, patients were divided into three groups: mild (n = 198), severe (n = 60), and critical (n = 15). CK‐MB, creatine kinase isoenzyme‐MB; MYO, myohemoglobin; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; COVID, coronavirus disease. ***P < .001
Figure 2
Figure 2
Levels of CK‐MB, MYO, ultra‐TnI, and NT‐proBNP were compared and analyzed between death and alive patients with COVID‐19. Till 23 March, 24 patients died among 273 cases. Two hundred forty‐six recovered and 3 still in hospital at severe situation (249 alive in total). CK‐MB, creatine kinase isoenzyme‐MB; MYO, myohemoglobin; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; COVID, coronavirus disease. ***P < .001
See this image and copyright information in PMC

Comment in

References

    1. Lu H, Stratton CW, Tang Y‐W. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92(4):401‐402. - PMC - PubMed
    1. Hui DS, I Azhar E, Madani TA, et al. The continuing 2019‐nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264‐266. - PMC - PubMed
    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727‐733. - PMC - PubMed
    1. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130‐137. - PMC - PubMed
    1. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967‐1976. - PubMed

Publication types

MeSH terms

LinkOut - more resources